Current Cancer Drug Targets

Papers
(The H4-Index of Current Cancer Drug Targets is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
The Expression of Glutaminases and their Association with Clinicopathological Parameters in the Head and Neck Cancers86
Micro-fragmented Fat Inhibits the Progression of Human Mesothelioma Xenografts in Mice45
FHOD3 Promotes the Progression of Lung Cancer by Regulating the Caspase-3-Mediated Signaling Pathway41
A Review on Patient-derived 3D Micro Cancer Approach for Drug Screen in Personalized Cancer Medicine37
Progress in Metabolic Studies of Gastric Cancer and Therapeutic Implications34
Etiology-based Molecular Characterization of Hepatocellular Carcinoma Reveals SQLE's Contribution to Immunosuppressive Microenvironment27
A Pilot Study of Anlotinib as a Combination Treatment in Advanced Nasopharyngeal Carcinoma26
Knockdown of PRKD2 Enhances Chemotherapy Sensitivity in Cervical Cancer via the TP53/CDKN1A Pathway26
TBOPP, a DOCK1 Inhibitor, Potentiates Cisplatin Efficacy in Breast Cancer by Regulating Twist-mediated EMT26
Expression, Prognostic Value, and Immune Infiltration of MTHFD Family in Bladder Cancer25
Silencing HEATR1 Rescues Cisplatin Resistance of Non-small Cell Lung Cancer by Inducing Ferroptosis via the p53/SAT1/ALOX15 Axis23
LMNB1/CDKN1A Signaling Regulates the Cell Cycle and Promotes Hepatocellular Carcinoma Progression18
Efficacy and Safety of Immunotherapy Combined with Anlotinib as First-Line Treatment in Older NSCLC Patients with PD-L1 Expression<50%16
Unveiling Novel Therapeutic Drug Targets and Prognostic Markers of Triple Negative Breast Cancer16
The Therapeutic Potential of Urolithin A for Cancer Treatment and Prevention14
Identification of ATM Mutation as a Potential Prognostic Biomarker for Immune Checkpoint Inhibitors Therapy14
Immune Checkpoint Inhibitors for Advanced Biliary Tract Cancer14
Development of Chromatin Regulator-related Molecular Subtypes and a Signature to Predict Prognosis and Immunotherapeutic Response in Head and Neck Squamous Cell Carcinoma14
Spinal KCC2 Mediates the Modulation Effect of HDAC2 on Bone Cancer Pain in Rats14
Combined RNAi of CTTN and FGF2 Modulates Cell Migration, Invasion and G1/S Transition of Hepatocellular Carcinoma through Ras/ERK Signaling Pathway14
Bioinformatics and Experimental Study Revealed LINC00982/ miR-183-5p/ABCA8 Axis Suppresses LUAD Progression14
0.041039943695068